AU765644B2 - mGluR5 antagonists for the treatment of pain and anxiety - Google Patents

mGluR5 antagonists for the treatment of pain and anxiety Download PDF

Info

Publication number
AU765644B2
AU765644B2 AU61984/99A AU6198499A AU765644B2 AU 765644 B2 AU765644 B2 AU 765644B2 AU 61984/99 A AU61984/99 A AU 61984/99A AU 6198499 A AU6198499 A AU 6198499A AU 765644 B2 AU765644 B2 AU 765644B2
Authority
AU
Australia
Prior art keywords
pain
mglur
mglur5
antagonist
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU61984/99A
Other languages
English (en)
Other versions
AU6198499A (en
Inventor
Hans Allgeier
Nicholas David Cosford
Peter Josef Flor
Fabrizio Gasparini
Conrad Gentsch
Stephen D. Hess
Edwin Carl Johnson
Rainer Kuhn
Mark Tricklebank
Laszlo Urban
Mark Andrew Varney
Gonul Velicelebi
Katharine Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
SIBIA Neurosciences Inc
Original Assignee
Novartis AG
SIBIA Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU765644(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821503.1A external-priority patent/GB9821503D0/en
Application filed by Novartis AG, SIBIA Neurosciences Inc filed Critical Novartis AG
Publication of AU6198499A publication Critical patent/AU6198499A/en
Application granted granted Critical
Publication of AU765644B2 publication Critical patent/AU765644B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
AU61984/99A 1998-10-02 1999-09-30 mGluR5 antagonists for the treatment of pain and anxiety Ceased AU765644B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9821503.1A GB9821503D0 (en) 1998-10-02 1998-10-02 Organic compounds
GB9821503 1998-10-02
US22081398A 1998-12-23 1998-12-23
US09/220813 1998-12-23
PCT/EP1999/007239 WO2000020001A1 (en) 1998-10-02 1999-09-30 Mglur5 antagonists for the treatment of pain and anxiety

Publications (2)

Publication Number Publication Date
AU6198499A AU6198499A (en) 2000-04-26
AU765644B2 true AU765644B2 (en) 2003-09-25

Family

ID=26314451

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61984/99A Ceased AU765644B2 (en) 1998-10-02 1999-09-30 mGluR5 antagonists for the treatment of pain and anxiety

Country Status (21)

Country Link
EP (1) EP1117403B1 (https=)
JP (1) JP2002526408A (https=)
KR (1) KR20010088832A (https=)
CN (1) CN1187048C (https=)
AT (1) ATE255894T1 (https=)
AU (1) AU765644B2 (https=)
BR (1) BR9914215A (https=)
CA (1) CA2345137A1 (https=)
DE (1) DE69913548T2 (https=)
DK (1) DK1117403T3 (https=)
ES (1) ES2213389T3 (https=)
HU (1) HUP0200553A3 (https=)
ID (1) ID29095A (https=)
IL (2) IL142047A0 (https=)
NO (1) NO20011440L (https=)
NZ (1) NZ510743A (https=)
PL (1) PL202906B1 (https=)
PT (1) PT1117403E (https=)
RU (1) RU2232017C2 (https=)
SK (1) SK4382001A3 (https=)
WO (1) WO2000020001A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
PT1345609E (pt) 2000-12-22 2005-08-31 Hoffmann La Roche Derivados de tetra-hidro-(benzo ou tieno)-azepina-pirazina como antagonistas de mglur 1
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
SE0303419D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 11
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
ES2610508T3 (es) 2006-11-22 2017-04-27 Clinical Research Associates, Llc Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
EP2557183A1 (de) 2011-08-12 2013-02-13 Siemens Aktiengesellschaft Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態
LT3303316T (lt) 2015-06-03 2020-05-11 F. Hoffmann-La Roche Ag Etinilo dariniai
CA3066711A1 (en) 2017-07-31 2019-02-07 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
EP3459939A1 (en) 2017-09-26 2019-03-27 Pragma Therapeutics Novel heterocyclic compounds as modulators of mglur7
KR102027368B1 (ko) * 2018-05-29 2019-10-01 서울대학교산학협력단 통증의 강도를 측정하는 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8974398A (en) * 1997-07-11 1999-02-08 Novartis Ag Pyridine derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2056983T3 (es) * 1988-03-21 1994-10-16 Boehringer Ingelheim Pharma Compuestos para inhibir la biosintesis de metabolitos de acido araquidonico derivados de lipoxigenasa.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8974398A (en) * 1997-07-11 1999-02-08 Novartis Ag Pyridine derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AGRIC BIOL CHEM, 1982, 46(1), 309-311 *
NEURO REPORT, MARCH 1998, 9(4), 731-735 *

Also Published As

Publication number Publication date
BR9914215A (pt) 2001-07-03
CA2345137A1 (en) 2000-04-13
NZ510743A (en) 2003-10-31
ES2213389T3 (es) 2004-08-16
NO20011440D0 (no) 2001-03-21
KR20010088832A (ko) 2001-09-28
CN1187048C (zh) 2005-02-02
NO20011440L (no) 2001-05-15
EP1117403A1 (en) 2001-07-25
EP1117403B1 (en) 2003-12-10
IL142047A0 (en) 2002-03-10
DE69913548T2 (de) 2004-09-23
AU6198499A (en) 2000-04-26
HUP0200553A2 (hu) 2002-07-29
ID29095A (id) 2001-07-26
JP2002526408A (ja) 2002-08-20
CN1321087A (zh) 2001-11-07
PL346876A1 (en) 2002-03-11
SK4382001A3 (en) 2001-08-06
PT1117403E (pt) 2004-04-30
RU2232017C2 (ru) 2004-07-10
IL142047A (en) 2007-09-20
DE69913548D1 (de) 2004-01-22
HUP0200553A3 (en) 2002-11-28
WO2000020001A1 (en) 2000-04-13
PL202906B1 (pl) 2009-08-31
ATE255894T1 (de) 2003-12-15
DK1117403T3 (da) 2004-04-13

Similar Documents

Publication Publication Date Title
AU765644B2 (en) mGluR5 antagonists for the treatment of pain and anxiety
US20010056084A1 (en) MGluR5 antagonists for the treatment of pain and anxiety
JP2002525298A (ja) トロンビン阻害剤の投与による炎症疾患の処置法
HUT77315A (hu) Loratadinszármazék allergiás és egyéb betegségek kezelésében való alkalmazásra
ZA200103322B (en) 5HT1 receptor agonists and metoclopramide for the treatment of migraine.
Lynch III et al. ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model
JP2012131829A (ja) そう痒状態の処置のためのｍｇｌｕｒ５アンタゴニストの使用
JP3832229B2 (ja) フェニルエテンスルホンアミド誘導体含有医薬
US10828368B2 (en) Therapeutic treatments using centhaquin
Li et al. Morphine-induced antinociception in the rat: supra-additive interactions with imidazoline I2 receptor ligands
Larsen et al. Medicinal chemistry of competitive kainate receptor antagonists
JPH11501934A (ja) ニコチニルアラニンと、グリシン抱合の阻害薬又はビタミンｂ６とを含む組成物
US6117879A (en) Methods of using moxonidine to inhibit nociceptive pain
WO2000037089A1 (en) Cyclic adenosine diphosphate ribose analogues for modulating t cell activity
US20130203817A1 (en) Novel Inhibitors of LYN Kinase
Renodon-Cornière et al. Probing the Role of Linker Substituents in Bisdioxopiperazine Analogs for Activity against Wild-Type and Mutant Human Topoisomerase IIα
KR20260027269A (ko) 폐섬유증 또는 섬유증을 동반한 폐 질환과 같은 질환의 치료 또는 예방에서의 화합물 1의 용도
Mattes et al. Serotonin type-4 (5-HT4) receptors as therapeutic targets: Past and future roles of 5-HT4 receptor agonists
Lees Studies of the Clinical Pharmacology of Perindopril: A New Inhibitor of Angiotensin Converting Enzyme

Legal Events

Date Code Title Description
SREP Specification republished
TH Corrigenda

Free format text: IN VOL 17, NO 38, PAGE(S) 1267 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX IN THE NAME OF NOVARTIS AG, SIBIA NEUROSCIENCES INC., SERIAL NO. 765644, INID (72), AMEND THE TWELFTH INVENTOR TO READ VELICELEBI, G.

FGA Letters patent sealed or granted (standard patent)